-
Mashup Score: 8ICER Publishes Final Evidence Report on Treatment for Pulmonary Arterial Hypertension - ICER - 2 month(s) ago
Independent appraisal committee voted that sotatercept demonstrated a net health benefit when compared to background therapy; sotatercept would achieve common thresholds for cost-effectiveness if priced between $17,900 to $35,400 per year.
Source: icer.orgCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 65Merck Drug for Rare High Blood Pressure Disorder Approved in US - 2 month(s) ago
Merck & Co. won US approval for a new treatment for a rare, dangerous form of high blood pressure that’s expected to be among the company’s hits as sales from successful older drugs begin fading later this decade.
Source: www.bloomberg.comCategories: General Medicine News, CardiologistsTweet-
A new hope! The FDA just approved sotatercept for PAH! Potentially revolutionary news for PAH as it is the first drug acting on a new mechanism (not being a vasodilator like PDE5i-ERA-prostanoids) My opinion here (thanks Madison Muller for contacting me) https://t.co/7vNLNRdade https://t.co/A2a0rmTt7A
-
-
Mashup Score: 2
Despite large, randomized controlled trials and guideline recommendations, patients with heart failure with reduced ejection fraction (HFrEF) continue to receive suboptimal guideline-directed medical treatment (GDMT). This study aimed to evaluate the potential effect of inpatient initiation of sodiu …
Source: pubmed.ncbi.nlm.nih.govCategories: General Medicine News, CardiologistsTweet-
@hvanspall @gcfmd @JJheart_doc @nl_pereira @JACCJournals Simultaneous inpatient prescription of GDMT has another key advantage: long-term maintenance of GDMT Only 7% had SGLT2i initiated during index HFH. 30-day rate of SGLT2i prescriptions was 96% with inpatient initiation vs 14.7% if outpatient initiation!!! https://t.co/PyxoCT1E6A https://t.co/7bOl1C01ub
-
-
Mashup Score: 7Peridevice Leak After Left Atrial Appendage Occlusion: Incidence, Mechanisms, Clinical Impact, and Management - 5 month(s) ago
Left atrial appendage occlusion is an increasingly adopted stroke prevention strategy in patients with atrial fibrillation. However, peridevice leaks …
Source: www.sciencedirect.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 71Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension – Recor Medical - 6 month(s) ago
Approval of the Paradise™ Ultrasound Renal Denervation system makes innovative hypertension treatment available for the first time in the U.S.Palo Alto, Calif. – November 7, 2023 – Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the U.S. Food and Drug Administration (FDA) has approved Recor’s Paradise™ Ultrasound…
Source: www.recormedical.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 5
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: investor.lilly.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 70Recor Medical and Otsuka Medical Devices Announce First FDA-Approved Renal Denervation System for the Treatment of Hypertension – Recor Medical - 6 month(s) ago
Approval of the Paradise™ Ultrasound Renal Denervation system makes innovative hypertension treatment available for the first time in the U.S.Palo Alto, Calif. – November 7, 2023 – Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) today announced the U.S. Food and Drug Administration (FDA) has approved Recor’s Paradise™ Ultrasound…
Source: www.recormedical.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 5
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: investor.lilly.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 5
The Investor Relations website contains information about Eli Lilly and Company’s business for stockholders, potential investors, and financial analysts.
Source: investor.lilly.comCategories: General Medicine News, CardiologistsTweet
-
Mashup Score: 42Eli Lilly stock gains on FDA nod for obesity drug (NYSE:LLY) - 6 month(s) ago
The U.S. FDA has approved Eli Lilly’s weight loss treatment, Zepbound, providing competition in the obesity drug market dominated by Novo Nordisk (NVO). Read more here.
Source: seekingalpha.comCategories: General Medicine News, CardiologistsTweet
For patients: Merck will charge $14,000 per vial , hence annual cost at $238,000 (every 3 weeks) ICER calculates a health-benefit price benchmark (HBPB, ie a price range that matches the clinical benefit) for sotatercept of $17,900- $35,400 per year.https://t.co/K0i4ihKIsr